3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Colorectal Neoplasms
26
Breast Neoplasms
21
Carcinoma, Non-Small-Cell Lung
19
Lung Neoplasms
15
Head and Neck Neoplasms
13
Rectal Neoplasms
11
Colonic Neoplasms
11
Prostatic Neoplasms
8
Pancreatic Neoplasms
7
Mouth Neoplasms
6
Glioblastoma
6
Neuroblastoma
5
Neoplasm Metastasis
5
Esophageal Neoplasms
5
Central Nervous System Neoplasms
5
Carcinoma
5
Unspecified Adult Solid Tumor, Protocol Specific
4
Triple Negative Breast Neoplasms
4
Recurrence
4
Precancerous Conditions
4
Ovarian Neoplasms
4
Oropharyngeal Neoplasms
4
Neoplasms
4
Liver Neoplasms
4
Laryngeal Neoplasms
4
Hypopharyngeal Neoplasms
4
Gliosarcoma
4
Carcinoma, Hepatocellular
4
Adenomatous Polyposis Coli
4
Sarcoma
3
Interventions
pembrolizumab
4
Nivolumab
3
toripalimab
2
sintilimab
2
Neoadjuvant Therapy
2
Celecoxib
2
tislelizumab
1
spartalizumab
1
relatlimab
1
regorafenib
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
denileukin diftitox
1
danvatirsen
1
camrelizumab
1
avelumab
1
atezolizumab
1
XELOX
1
Taxes
1
Surgical Procedures, Operative
1
Radiation Dose Hypofractionation
1
Paclitaxel
1
Megestrol Acetate
1
Medroxyprogesterone Acetate
1
Ipilimumab
1
Induction Chemotherapy
1
Immunotherapy
1
Immunoglobulin G
1
Immune Checkpoint Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Turcot syndrome
×
Celecoxib
×
Clear all
NCT06903858
2026-05-22
PICC-3
Sun Yat-sen University
Phase 2
Recruiting
105 enrolled
NCT03926338
2025-11-20
PICC
Sun Yat-sen University
Phase 2
Recruiting
270 enrolled